Check out the original article from the Lancet Haematology here.
Tags: autologous stem cell transplantationblood cancerbortezomibcancercancer progressionchemochemotherapydexamethasonedouble autologous haematopoietic stem-cell transplantationhaematopoietic stem cell transplantationhematologyhematopoietic cell transplantationHematopoietic stem-cell transplantationHSCTmalignancyMMmultiple myelomamyelomaoncologyoverall survivalprogression-free survivalsecond primary malignanciesstem cell transplantstem cell transplantationsurvival outcomesthalidomidevtd